Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival

Author： Kang Eun   Im Seock-Ah   Oh Do-Youn   Han Sae-Won   Kim Jin-Soo   Choi In   Kim Jin   Kim Yu   Kim Jee   Kim Tae-You   Lee Jong   Bang Yung-Jue   Lee Keun-Wook  

Publisher： Springer Publishing Company

ISSN： 1436-3291

Source： Gastric Cancer, Vol.16, Iss.4, 2013-10, pp. : 581-589

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

By Pfeiffer Per   Nielsen Dorte   Yilmaz Mette   Iversen Anja   Vejlø Christian   Jensen Benny Vittrup  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 697-701

Informa Healthcare

Access to resources Recommend Favorite

Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer

By Shim Hyun  

Gastric Cancer, Vol. 14, Iss. 3, 2011-08 ,pp. : 249-256

Springer Publishing Company

Access to resources Recommend Favorite

Irinotecan, leucovorin and 5fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer

By                      

Oncology Letters, Vol. 4, Iss. 4, 2012-01 ,pp. : 751-754

Spandidos Publications

Access to resources Recommend Favorite

Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer

By Shitara Kohei  

Gastric Cancer, Vol. 14, Iss. 2, 2011-06 ,pp. : 155-160

Springer Publishing Company

Access to resources Recommend Favorite

Nordic 5-Fluorouracil/Leucovorin Bolus Schedule Combined with Oxaliplatin (Nordic FLOX) as First-line Treatment of Metastatic Colorectal Cancer

By Sørbye Halfdan   Dahl Olav  

Acta Oncologica, Vol. 42, Iss. 8, 2003-12 ,pp. : 827-831

Informa Healthcare

Access to resources Recommend Favorite